NewsRx

Search our medical news database

Alcoholism News and Articles

Return to Library

Recent Alcoholism News and Articles


Researchers from University of Minnesota Discuss Findings in Clinical Trials Research

2013 JAN 21 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Drugs and Therapies. According to news reporting out of Minneapolis, Minnesota, by NewsRx editors, research stated, "Clinical trials for alcoholism have historically regarded alcohol consumption as the primary outcome. In a subset of trials, quality of life (QOL) has been considered as a secondary outcome."

Our news journalists obtained a quote from the research from the University of Minnesota, "Joint latent-variable modeling techniques may provide a more accurate and powerful simultaneous analysis of primary and secondary outcomes in clinical trials. The goal of this study was to evaluate longitudinal associations between treatment status, alcohol consumption, and QOL in the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. A total of 1,383 alcohol-dependent patients were randomized to 9 treatment groups. Percent heavy drinking days (PHDD) and health-related QOL from the 30 days preceding baseline, week 16, and week 52 were calculated using the Form 90 and the Medical Outcomes Study Health Survey Short Form-12 (SF-12), respectively. Latent profile analysis (LPA) was conducted to determine an appropriate number of latent states to represent PHDD and QOL. Subsequently, univariate and coupled hidden Markov models (for PHDD and SF-12 mental health, and PHDD and SF-12 physical) were fit to the data. LPA suggested that PHDD should be represented by 3 latent states and that each SF-12 scale should be represented by 2 states. Joint modeling results suggested that (i) naltrexone significantly predicted decreased PHDD (p < 0.05), and marginally predicted improved mental health QOL via decreased PHDD (p < 0.10), and (ii) that the combinations of naltrexone and combined behavioral intervention (CBI), and acamprosate and CBI, each predicted significantly improved physical QOL (p < 0.05), and marginally predicted decreased PHDD via improved physical QOL (p < 0.10). This study illustrates a powerful and novel statistical approach for simultaneously evaluating the impact of treatments on primary and secondary outcomes in clinical trials."

According to the news editors, the research concluded: "This study also suggests that behavioral interventions may impact drinking behavior through their ameliorative effects on QOL."

For more information on this research see: Simultaneous Modeling of the Impact of Treatments on Alcohol Consumption and Quality of Life in the COMBINE Study: A Coupled Hidden Markov Analysis. Alcoholism-Clinical and Experimental Research, 2012;36(12):2141-2149. Alcoholism-Clinical and Experimental Research can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA.

Our news journalists report that additional information may be obtained by contacting J.J. Prisciandaro, University of Minnesota, Sch Public Hlth, Div Biostat, Minneapolis, MN 55455, United States.

Keywords for this news article include: Minnesota, Minneapolis, United States, Quality of Life, Drugs and Therapies, Clinical Trial Research, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC

NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook